Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1420399
This article is part of the Research Topic Monoclonal Antibodies and Immune Checkpoint Inhibitors in the treatment of Cancer View all 27 articles

Prognostic Biomarkers for Immunotherapy in Esophageal Cancer

Provisionally accepted
Xu Tong Xu Tong 1Meiyuan Jin Meiyuan Jin 1Lulu Wang Lulu Wang 2Dongli Zhang Dongli Zhang 2Yuping Yin Yuping Yin 3*Qian Shen Qian Shen 4*
  • 1 Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 2 Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, China
  • 3 Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 4 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

The final, formatted version of the article will be published soon.

    Esophageal cancer (EC), a common type of malignant tumor in the world, ranks as the sixth highest contributor to cancer-related mortality worldwide. Due to the condition that most patients with ECthe majority of EC patients are diagnosed at advanced or metastatic status, the efficacy of conventional treatments including surgery, chemotherapy and radiotherapy is limited, resulting in a gloomy dismal 5-year overall survival (OS) rate. In recent years, the application of immune checkpoint inhibitors (ICIs) has presented a novel therapeutic avenue for EC patients.Currently, bBoth ICIs monotherapy and immunotherapy combined with chemotherapy or chemoradiotherapy (CRT) have demonstrated marked benefits for patients with advanced EC. In the realm of perioperative treatment pattern, aAdjuvant or neoadjuvant therapy incorporating immunotherapy has also demonstrated displayed promising prospects in the context of perioperative treatment. Nonetheless, due to the variable response observed among patients undergoing immunotherapy, it is of vital importance to identify predictive biomarkers for stratifying patient stratifications, to facilitate identification of in order to recognize the subgroups who may derive greater benefits from immunotherapy. In this review, we summarize validated or potential biomarkers for immunotherapy in EC from in three dimensions: tumor-cell-associated biomarkers, tumor-immune microenvironment (TIME)-associated factors, and host-associated biomarkers, so as to provide a theoretical foundation to inform tailored therapy for individuals diagnosed with EC.

    Keywords: Esophageal cancer, , Immunotherapy,, biomarkers,, ICIs,, time

    Received: 20 Apr 2024; Accepted: 05 Sep 2024.

    Copyright: © 2024 Tong, Jin, Wang, Zhang, Yin and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yuping Yin, Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Qian Shen, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.